News Sentiment

LEXX sentiment intelligence

Lexaria Bioscience Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.65 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+15.4% over one week, +5.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Lexaria Bioscience narrows Q3 loss to $(0.08) per share

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 15.4% Price confirming higher
Trend fit Trend inactive 5.2% over four weeks
Fair value -60.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
TradingKey 8
Market source 6
TradingView 5
Investing News Network 5
ACCESS Newswire 5
simplywall.st 3
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 18
Analyst action 2
Balance sheet 2
Deals and strategy 2
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
scanx.trade Direct company coverage

Lexaria Bioscience narrows Q3 loss to $(0.08) per share

Lexaria Bioscience reported a Q3 loss per share of $(0.08), an improvement from $(0.21) last year, and better than the analyst estimate of $(0.09). This indicates effective expense management and progress in financial operations, though the company remains unprofitable. The artic

Tone
Positive 65/100
Event
Analyst action
Published
13 Jul 2026 23:10
Source
scanx.trade
TradingView Direct company coverage

Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary

Lexaria Bioscience Corp. (LEXX) reported its 2026 quarterly results with $0 revenue and a diluted loss per share of ($0.08), though its net loss narrowed significantly from the prior year. The company is advancing R&D in GLP-1, GIP, glucagon, and CBD programs, and raised approxim

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid

Lexaria Bioscience reported a narrower net loss of $5.0 million for the nine months ended May 31, 2026, compared to $9.2 million a year prior, primarily due to reduced R&D spending. Despite this, the company warned about its ability to continue as a going concern beyond Q1 fiscal

Tone
Negative 38/100
Event
Balance sheet
Published
13 Jul 2026 20:10
Source
Stock Titan
Investing News Network Direct company coverage

Lexaria Updates Business Development

Lexaria Bioscience Corp. (NASDAQ: LEXX) has reported positive outcomes from recent meetings at the 2026 BIO International Convention, focusing on partnerships for its DehydraTECH™ drug delivery platform. The company noted a significant interest in the GLP-1 sector, particularly r

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 06:11
Source
Investing News Network
Investing.com India Direct company coverage

Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com

Lexaria Bioscience Corp. (NASDAQ:LEXX) held discussions with potential pharmaceutical partners at the 2026 BIO International Convention, focusing on the GLP-1 sector and the company's DehydraTECH technology. Despite a stock decline, analysts predict profitability for Lexaria this

Tone
Positive 65/100
Event
Deals and strategy
Published
06 Jul 2026 15:40
Source
Investing.com India
Stock Titan Direct company coverage

Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows

Lexaria Bioscience (NASDAQ: LEXX) reported successful business development meetings at the 2026 BIO International Convention, primarily focusing on GLP-1 drug applications and its DehydraTECH technology. The company noted a shift in industry focus towards balancing GLP-1 weight-l

Tone
Positive 74/100
Event
Market update
Published
06 Jul 2026 12:40
Source
Stock Titan
Finviz Direct company coverage

LEXX - Lexaria Bioscience Corp Forecast, Target Price

This article provides a detailed financial overview and forecast for Lexaria Bioscience Corp (LEXX), including key financial metrics, stock performance data, and analyst recommendations. It highlights the company's last closing price, market capitalization, and various profitabil

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 03:39
Source
Finviz
TradingView Direct company coverage

Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX)

This article provides an overview of Lexaria Bioscience Corp. (NASDAQ: LEXX) financial data and analyst estimates. It includes current stock price, historical performance, market capitalization, and upcoming earnings report dates. The company's stock has seen a decrease over the

Tone
Negative 29/100
Event
Earnings
Published
26 Jun 2026 07:11
Source
TradingView
The Daily Corinthian Direct company coverage

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria Bioscience Corp. has initiated dosing for its Human Pilot Study #7 (GLP-1-H26-7), evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy® tablets. The 5-week study aims to confirm superior safety, tolerability, and pharmacokinetic performan

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 13:43
Source
The Daily Corinthian
Stock Titan Direct company coverage

Lexaria starts 5-week human GLP-1 study using tablet and capsule forms

Lexaria Bioscience Corp. has initiated a 5-week human pilot study (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide (DHT-sema) compositions in both tablet and capsule forms against Novo Nordisk's Wegovy tablets. The study, which began dosing on June 14, 2026, aims to ass

Tone
Positive 67/100
Event
Market update
Published
25 Jun 2026 12:41
Source
Stock Titan
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lexaria Bioscience Corp (LEXX), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 26, 2026, LEXX has a price momentum score of 5.64 and is suitable for range-bound swing tradi

Tone
Negative 28/100
Event
Market update
Published
25 Jun 2026 12:39
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Lexaria Bioscience Corp (LEXX), which currently has a financial score of 6.70 out of 10, ranking 139th in the Pharmaceuticals industry. Despite a robust overall financial status, the company exhibits low operating efficiency. Its lates

Tone
Negative 36/100
Event
Market update
Published
24 Jun 2026 12:10
Source
TradingKey
Investing News Network Direct company coverage

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Lexaria Bioscience Corp. announced that its Animal Study GLP-1-A26-1, evaluating novel DehydraTECH-semaglutide and DehydraTECH-CBD compositions, has begun dosing on schedule. The study aims to develop alternative formulations to SNAC, currently used in Novo Nordisk's oral GLP-1 p

Tone
Positive 71/100
Event
Market update
Published
23 Jun 2026 14:10
Source
Investing News Network
Stock Titan Direct company coverage

Lexaria starts animal GLP-1 study, adds Australian patent

Lexaria Bioscience has begun dosing for Animal Study #1 (GLP-1-A26-1) on schedule, evaluating DehydraTECH-semaglutide and DehydraTECH-CBD GLP-1 compositions in rats to discover alternative formulations to SNAC for new intellectual property. Results are anticipated by early Septem

Tone
Positive 74/100
Event
Earnings
Published
23 Jun 2026 13:09
Source
Stock Titan
TradingView Direct company coverage

Lexaria Bioscience Corp. Financial Disclosures & SEC Filings

This article provides an extensive list of Lexaria Bioscience Corp.'s SEC filings and financial disclosures, including quarterly and annual earnings reports from 2020 to 2026. Each entry offers a brief summary of the company's financial performance, revenue, net losses, and R&D a

Tone
Negative 36/100
Event
Earnings
Published
18 Jun 2026 23:09
Source
TradingView
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Lexaria Bioscience Corp (LEXXW), noting that key financial ratios such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. It briefly outlines the stock's current price and market capitalization. The analysis from Trad

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lexaria Bioscience Corp (LEXXW), detailing its support, resistance, various technical indicators, and moving averages. It highlights that no buy or sell signals are currently indicated by the technical indicators or moving averages, w

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 18:10
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXXW) Institutional Confidence — TradingKey

This article provides an overview of the institutional confidence in Lexaria Bioscience Corp (LEXXW), detailing changes in institutional shareholding. Key investors like Clear Street Group Inc. and HRT Financial LP have increased their stake, while others like Heights Capital Man

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 07:09
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Lexaria Bioscience Corp (LEXX), including its business segments, regional revenue, and profit contribution. The report indicates that relevant financial data for these categories have not yet been disclosed by the comp

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 07:09
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Lexaria Bioscience Corp (LEXXW) from TradingKey. It indicates that relevant data for EPS, revenue, and net profit forecasting have not yet been disclosed by the company. The article serves as a placeholder for future financial growth

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lexaria Bioscience Corp (LEXX) has an earnings forecast score of 8.00, placing it 55th in the Pharmaceuticals industry. Analysts have set an average price target of $6.00, with a range from $4.00 to $6.00, and a "Buy" rating based on one analyst. The company's expected revenue fo

Tone
Positive 76/100
Event
Earnings
Published
17 Jun 2026 20:40
Source
TradingKey
Stock Titan Direct company coverage

Lexaria says GLP-1 drugs are moving into more diseases and markets

Lexaria Bioscience reports on the accelerating adoption and expanding indications for GLP-1 drugs, noting their increasing use for weight loss and various comorbidity treatments. The company highlights its DehydraTECH platform's potential to improve oral GLP-1 absorption and redu

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 13:40
Source
Stock Titan